STENOCARE

In Denmark and across Europe, patients are encountering medication shortages at pharmacies due to supply disruptions. STENOCARE is diligently monitoring the entire supply chain to proactively mitigate supply risks and ensure uninterrupted access to our products for patients.

For full article: https://stenocare.com/investor-relations/announcements/B0B32283360E6B69/

STENOCARE update on our strong Danish product pipeline.

We are sharing our plans and work with our strong Danish product pipeline across its four stages from concept to commercialization. Meeting Danish Drug Standards (DLS) Stenocare has a full product program of 2nd generation medical cannabis oil products (stage 3+4), specialized products with unique potency profiles (stage 2) and also 3rd generation product program that can revolutionize the industry (stage 1).

For full press release:
https://stenocare.com/investor-relations/announcements/25C5BEBBF032D49E/

An interesting article about the recreational legalization of cannabis is expected to further accelerate the growth of medical cannabis in Germany. It has the potential to reduce handling complexity for suppliers, doctors, and pharmacies. We look forward to commencing the sale of our medical cannabis oil product soon.
For full article:

Germany Publishes Draft Law for Pillar 1 Confirming Plans to Declassify Cannabis as a Narcotic - Business of Cannabis Germany’s Ministry of Health has officially published its draft law for ‘Pillar 1’ of its plans to liberalise access to adult-use cannabis. Alongside the 163-page draft, the government has published a Q&A document revealing that as the law does not require the approval of the Bundesrat, ‘it ...

Today, we announced that our Nasdaq Rights Issue was subscribed by 127%.

We are honored to welcome many new shareholders and grateful for the support of our existing shareholders.

On behalf of the entire Stenocare team, we would like to express our sincere gratitude. Thank you, and let's embark on the exciting journey of pursuing growth opportunities in the medical cannabis industry.

For full announcement: https://stenocare.com/investor-relations/announcements/47BECCD7FB0B764D/

NEWS: We are proud and excited to have a capacity like Hans Wittrup on board as an investor, shareholder and recognized capacity in our space.
Inspired about the potential of medical cannabis when prescribed by doctors to patients in pain, Hans Wittrup, M.D., Ph.D., has decided to join the ongoing rights issue with a pre-subscription of DKK 750.000.
Hans Wittrup comments: It impresses me that Stenocare - in just a few years, and to my knowledge as the only European player - has had medicinal cannabis oil products approved and sales completed in both Denmark and now 5 other countries, including Europe's largest market, Germany. I believe that Stenocare can play an important role in this development and would like to be involved in this, both as an investor and in other ways where it may be relevant.

We are inviting investors to join our Unit Right Issue in May/June. Please visit our investor page for more details: https://stenocare.com/share-issue-2023/

For full announcement: https://stenocare.com/investor-relations/announcements/F2EFF3FBBF658B76/

NEWS: STENOCARE has developed an IT-platform, that enables doctors to launch and operate Online Clinics. This will grow sales of the Stenocare products as more patients have easy access to treatment.

We are inviting investors to join our Unit Right Issue in May/June. Please visit our investor page for more details: https://stenocare.com/share-issue-2023/

For full announcement: https://stenocare.com/investor-relations/announcements/344289C570338EB6/

Exciting Opportunity to Invest in the European Medical Cannabis Industry: Subscription Starts on May 24th with a Favorable Offer on New Stenocare Shares.

Learn more about the UNIT Share Issue - Click Here:
https://stenocare.com/share-issue-2023/

One of the five Stenocare markets, Australia, is predicted to become larger than the current leading market in the medical cannabis industry. Australia has experienced remarkable growth in the past few years.

For full article click here:

Australia's medical cannabis sales might surpass Canada's in near future Australia's medical ma*****na industry is experiencing brisk growth in patients and sales and might soon surpass Canada’s medical sector.

Germany ready to legalize cannabis for consumers.
After several attempts with the EU, German politicians have now found a path to legalise recreational cannabis. This will happen through a two-phased model under a five-year pilot programme: 1) Allowing people to grow cannabis at home or via social clubs, and 2) Pilot shops that sell cannabis. Stenocare expects this move to further accelerate European acceptance of MEDICAL cannabis, as authorities and society are exposed to the wider use of cannabis.

For full article:

Europe Takes Major Step To Wholesale Cannabis Reform As German Adult-Use Plan Unveiled - Business of Cannabis IN a major break from the European era of prohibition both Germany and Czechia are set to legalise the use of cannabis. Following months of talks with the European Commission the neighbouring countries appear to have negotiated a suitable legal pathway to wholesale cannabis reform. While Germany’s...

The STENOCARE Quality Team is conducting an audit of our Canadian supplier, which is one of the few with an EU-GMP certification for their entire cultivation and production process. To ensure compliance with our high standards, Søren, Jette, and Hassan have been spending two full days on-site, inspecting every aspect of the supplier's operations and reviewing all relevant Standard Operating Procedures.
AgMEDICA Bioscience, our supplier, operates an indoor cultivation facility that includes a dedicated production line designed specifically for Stenocare to meet the strict quality and uniformity requirements of the European market.

The Q4 Report highlighted the approval of four new products, expansion into Norway, and impressive sales of 2.8 million Danish kroner, showcasing the company's commitment to growth and innovation.

Listen to the full interview with Stenocares CEO Thomas Skovlund Schnegelsberg and Helge Larsen from Proinvestor.

Stenocare sælger nu i fem lande og står stærkt i 2023 Hvordan lykkes Stenocare med at vinde frem, når flere spillere på markedet for receptbaserede cannabisprodukter falder på stribe? Stenocare gik ind i tre nye...

Great news! Our Q4 2022 report has just been released, and we're happy to announce that we're back in business 😊.

We achieved a sales record of 2.8 million DKK in Q4, and we also hit two huge milestones.

We've been approved to sell a new product in Denmark, and we were approved to enter Norway with three of our products.

With a presence in five countries, we're well-positioned to take our business to the next level. A great end to the year!

Fun fact: Stenocare high-tech indoor cultivation facility is using HEPA filters to control the air quality that is similar to operation theatres in hospitals.

At Stenocare we minimize potential contamination of the plants from external sources. Erik from our engineering team has been testing this big filter together with external experts. They found the efficiency of the HEPA filter and the air quality is similar to the operation theatres in hospitals. Perhaps a little over the top, but we like to be on the safe side 😊.

Our HEPA filter remove airborne contaminants and allergens, and it also ensures that the grow room environment is free from pathogens that could potentially harm the plants.

HEPA filters are commonly used in operating theaters to help maintain a clean and sterile environment. Operating theaters require a high level of air quality control to minimize the risk of infection and ensure patient safety.

HEPA (High-Efficiency Particulate Air) filter is a type of air filter that is designed to remove very small particles from the air, including dust, pollen, pests and smoke. The HEPA filter refers to a filter that has been tested and certified to capture extremely small particles. HEPA is a European standard for HEPA filters that requires a minimum efficiency of 95% for capturing particles with a diameter of 0.3 microns (equal to 0.03 mm).

We are pleased to be part of a significant meeting focused on creating a new monograph for The European Pharmacopoeia.

This monograph will serve as the standard for the production and approval of cannabinoid-based medicinal products in Europe and will be recognized as the authoritative reference for the industry.

Søren Kjær, COO, and Thomas Skovlund Schnegelsberg, CEO, are honored to be working with the Danish Medicines Agency on this important endeavor.

Medical cannabis in Norway: STENOCARE participated in a public debate meeting in Oslo alongside key medical experts and politicians from the Norwegian Parliament.

We discussed ways to improve the quality of life for patients, provide easier access to treatment with medical cannabis, ensure patient safety, and help patients move from the illegal market to the safety of medical clinics and pharmacies.

The focus of the debate was on how to best benefit patients. This could be a step towards legalization and regulation in Norway, and STENOCARE was happy to share our experiences from the Danish Pilot Programme with Norwegian stakeholders in order to help the process.

Thank you to MedCan Norge, Normal Norge, and FTR Oslo for inviting us to contribute and for hosting this important debate meeting.

The meeting was recorded and can be viewed here: https://fb.watch/ibf6rcqSfv/

What's in store for medical cannabis in 2023 - read the article from BusinessCann and get interesting insight about the 2023 predictions for the medical cannabis industry. STENOCARE CEO Thomas Skovlund Schnegelsberg also share his perspectives in the article.

For full article:
https://businesscann.com/whats-in-store-for-the-european-cannabis-industry-in-2023-part-1/

We are happy to share that the first shipment of Stenocare medical cannabis oil products has arrived in Norway and are now ready for nationwide sales and delivery to patients with a prescription.

We are starting the new year with an important milestone. We have delivered the first CBD oil product batch to the Danish market, and our sales can begin.

It has been a year of hard work for our regulatory team to reach this important milestone and therefore our team can be extra proud with our delivery today.

STENOCARE enter Norway and now exclusively cover all Scandinavian countries.

“We are proud to be the only supplier in Scandinavia, and we look forward to follow the treatment effect for patients in Norway”. Stenocare is now active in 5 countries with 11 MC oil products.

See link in comment field for full article.

Breakthrough results from new oil study. Stenocare and Solural Pharma have reached groundbreaking results from their study of a new MC oil formulation.

The study shows that the new formulation dramatically enhances the bioavailability of oil (i.e. uptake in the blood), regardless of meal consumption and inter-individual biological differences. The findings may have the potential to formulate new MC products with vastly improved characteristics in the treatment of chronical pain and a variety of indications and diseases.

See link in comment field for full article.

Shipment to the UK
The Stenocare team is in Canada working with the AgMEDICA team to prepare a shipment of products for UK patients. Next week these products will be on the pharmacy shelves in the UK.

Stenocare are expanding to our fourth market: “We can deliver oil products to 600 pharmacies and 3000 doctors in Australia”.
Read the full story here:
https://stenocare.com/investor-relations/announcements/626D83643ABF0CC0/

Rolf Steno, Stenocare CCO and Rob Jenny, Cannvalate Business Development Manager closing the partnership agreement in Brisbane Australia.

STENOCARE CEO Thomas Skovlund Schnegelsberg interview with BusinessCann about the expansion ambitions for the company.

Read the full article here:
https://businesscann.com/stenocare-plans-to-get-even-more-aggressive-in-expansion-ambitions-as-stock-price-jumps-double-digits/

STENOCARE CEO is a speaker and the chairman of the Central & Eastern European Track at “Cannabis Business Europe 2022” in Frankfurt this week – where he is sharing industry insights.

The key message for the young European medical cannabis industry is: ”Go pharma or go home”.
https://www.worldclassbusinessleaders.com/events/CBE22

Stenocare is honored to be speaking at the first Swedish medical cannabis conference in Stockholm.

Several hundred Swedish doctors are today learning about the Endocannabinoid system from a researcher, hearing from a Danish doctor how treatment of patients is managed – and having the opportunity to ask questions and network.

Today is extra special. We have delivered the first batch of oil-products to the Danish market. We have worked two years towards this important day, and now sales can begin again.